000 | 01988 a2200577 4500 | ||
---|---|---|---|
005 | 20250517123431.0 | ||
264 | 0 | _c20170316 | |
008 | 201703s 0 0 eng d | ||
022 | _a1096-0295 | ||
024 | 7 |
_a10.1016/j.yrtph.2016.10.020 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aGorain, Bapi | |
245 | 0 | 0 |
_aComparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion. _h[electronic resource] |
260 |
_bRegulatory toxicology and pharmacology : RTP _cDec 2016 |
||
300 |
_a20-31 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article | ||
650 | 0 | 4 | _aAdministration, Oral |
650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xadministration & dosage |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntihypertensive Agents _xadministration & dosage |
650 | 0 | 4 |
_aBiomarkers _xblood |
650 | 0 | 4 |
_aBody Weight _xdrug effects |
650 | 0 | 4 |
_aBrain _xmetabolism |
650 | 0 | 4 | _aChromatography, Liquid |
650 | 0 | 4 |
_aDrinking _xdrug effects |
650 | 0 | 4 | _aDrug Carriers |
650 | 0 | 4 | _aDrug Compounding |
650 | 0 | 4 |
_aEating _xdrug effects |
650 | 0 | 4 | _aEmulsions |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aNanomedicine _xmethods |
650 | 0 | 4 | _aNanoparticles |
650 | 0 | 4 |
_aOils _xchemistry |
650 | 0 | 4 |
_aOlmesartan Medoxomil _xadministration & dosage |
650 | 0 | 4 |
_aOrgan Size _xdrug effects |
650 | 0 | 4 | _aPermeability |
650 | 0 | 4 | _aRats, Wistar |
650 | 0 | 4 | _aReproducibility of Results |
650 | 0 | 4 | _aRisk Assessment |
650 | 0 | 4 | _aTandem Mass Spectrometry |
650 | 0 | 4 | _aTissue Distribution |
650 | 0 | 4 | _aToxicity Tests, Subchronic |
650 | 0 | 4 |
_aWater _xchemistry |
700 | 1 | _aChoudhury, Hira | |
700 | 1 | _aTekade, Rakesh Kumar | |
700 | 1 | _aKaran, Saumen | |
700 | 1 | _aJaisankar, P | |
700 | 1 | _aPal, Tapan Kumar | |
773 | 0 |
_tRegulatory toxicology and pharmacology : RTP _gvol. 82 _gp. 20-31 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.yrtph.2016.10.020 _zAvailable from publisher's website |
999 |
_c26578655 _d26578655 |